

## Disclosures

### Personal Commercial (1)

| Company Name | Relationship Category                                     | Compensation Level | Topic Area(s)                       |
|--------------|---|--------------------|-------------------------------------|
| Shockwave    | Other - I am blinded investigator for the COSIRA II study | None (\$0)         | Invasive CV Angio and Interventions |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (4)

| Non-Commercial Entity Name  | Relationship Category   | Compensation Level | Topic Area(s)            |
|---|---|--------------------|--------------------------|
| <b>Self</b>   |   |                    |                          |
| American Heart Association  | Other - Vice Chair of the Council of Clinical Cardiology and Chair of the Fellows in Training Committee | None (\$0)         | General Cardiology       |
| Hamilton Health Sciences Corporation (through its Population Health Research Institute) (PHRI)<br><i>† I am site PI for the Complete 2 Trial and on the Adjudications Committee</i> | Research/Research Grants  | None (\$0)         | Acute Coronary Syndromes |
| NYS<br><i>† none</i>  | Other - Member of the Cardiac Advisory Committee  | None (\$0)         | General Cardiology       |
| Society of Cardiac Angiography and Intervention   | Other - Vice Chair of the SCAI Fellows Course Planning  | None (\$0)         | General Cardiology       |

### Clinical Trial Enroller (3)

| Trial Name        | Trial Sponsor        | Trial Funding Source |
|-------------------|----------------------|----------------------|
| AGENT DCB Stance  | Boston Scientific    |                      |
| The Magical Trial | concepts Medical     |                      |
| EXACT 2 Trial     | XyloCor Therapeutics |                      |

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

*† Commercial Funding Source | ‡ Trial Name*

## Agreement

### Certified Education Attestation | Signed on 1/11/2026

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

### Confidentiality, Disclosure and Assignment Agreement | Signed on 1/11/2026

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

### Embargo | Signed on 1/11/2026

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

### On-Going Obligation Agreement | Signed on 1/11/2026

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.